Ranibizumab biosimilar - Samsung Bioepis

Drug Profile

Ranibizumab biosimilar - Samsung Bioepis

Alternative Names: SB-11

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samsung Bioepis
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Age-related macular degeneration

Most Recent Events

  • 14 Mar 2018 Phase-III clinical trials in Age-related macular degeneration in United Kingdom, Russia, Poland, India, Hungary, Germany, Czech Republic, USA, South Korea (Intravitreous) (EudraCT2017-000422-36) (NCT03150589)
  • 14 May 2017 Samsung Bioepis plans a phase III trial for Age-related macular degeneration (In adults, In elderly) in South Korea (Intravitreous) (NCT03150589)
  • 10 May 2017 Preclinical trials in Age-related macular degeneration in South Korea (Intravitreous) (NCT03150589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top